YOLFTbeta
BioNxt Solutions Inc.

BioNxt Solutions Inc.

BXT · XETRA · Healthcare / Drug Manufacturers - Specialty & Generic

0.175EUR-0.03 (-12.50%)

Price History

Full chart

Market Stats

Previous Close0.20
Open0.165
Day Range0.165 – 0.1825
52-Week Range0.17 – 0.46
Volume3.17K
Market Cap31.71M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta1.50
50-Day Avg0.2145
200-Day Avg0.2911

About

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Hugh A. D. Rogers B.Sc., LL.B
  • Headquarters1928 Linden Road, Vancouver, BC, Canada, V6M 1E7, Germany
  • Websitehttps://www.bionxt.com

Leadership

  • Mr. Hugh A. D. Rogers B.Sc., LL.BCo-Founder, CEO & Director · b. 1980
  • Dr. Raimar Lobenberg Ph.D.Co-Founder & Director · b. 1966
  • Mr. Wolfgang ProbstCo-Founder, CFO & Corporate Secretary · b. 1982
  • Dr. Florian A. SahrHead of Project Management
  • Dr. Wolfgang WagnerHead of Research & Development

Financials

Income Statement

Currency: CAD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue286.50K297.44K372.25K26.98K0
Growth (%)-+3.82%+25.15%-92.75%-100.00%
Cost of Revenue87.02K101.83K0--
Gross Profit199.48K195.62K372.25K--
Gross Margin69.63%65.77%100.00%--
Operating Expense16.51M6.24M6.76M--
Operating Income-16.31M-6.04M-6.39M-4.57M-6.05M
Operating Margin-5692.90%-2032.30%-1715.86%-16925.66%-
EBITDA--11.51M-6.48M-4.32M-5.77M
EBITDA Margin--3870.27%-1742.02%-16025.15%-
Net Income-20.64M-12.38M-7.72M-5.31M-7.03M
Net Income Margin-7203.23%-4160.84%-2074.68%-19683.18%-
R&D3.34M2.11M2.55M1.43M800.74K
R&D as % of Total Revenue1166.97%709.58%685.97%5301.50%-
Interest Expense731.87K1.14M1.04M985.15K1.44M
Interest Expense % of Total Revenue255.45%384.13%280.07%3650.72%-

Balance Sheet

Currency: CAD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.73M1.61M1.27M569.36K591.68K
Total Liabilities8.06M5.74M6.55M8.43M9.96M
Total Equity1.67M-4.13M-5.28M-7.86M-9.37M
Cash1.35M136.20K363.65K32.35K55.26K
Net Debt3.29M4.20M4.53M4.25M5.89M

Cash Flow

Currency: CAD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--12.16M-6.23M-5.17M-3.03M-5.20M
Financing Cash Flow-16.23M5.02M5.29M2.64M5.13M
Capital Expenditure0452.35K3.86K201.42K00
Free Cash Flow--12.61M-6.23M-5.37M-3.03M-5.20M
FCF to OCF-103.72%100.06%103.90%100.00%100.00%

Earnings

Report DateSep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------
EPS Actual-0.05-0.03-0.05-0.04-0.07-0.03-0.05-0.04-0.02-0.08-0.02-0.01-0.02-0.06-0.01-0.02-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01
Surprise---------------------------
Timing---------------------------

Key Statistics & Ratios

Market Cap31.71M
Enterprise Value38.06M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3172.89
Price / Book22.59
EPS-0.04
Book Value-0.0287
Revenue (TTM)15.82K
Gross Profit (TTM)15.82K
EBITDA-6.68M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-387.49%
Shares Outstanding136.09M
Shares Float128.57M
Beta1.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%